Restoring lipid homeostasis to redefine Alzheimer’s disease
MCM6 is developing disease-modifying treatments for Alzheimer’s disease for patients who carry APOE4, the largest genetic risk group.
We aim to restore lipid homeostasis using stem cell-based technology and a 3D multicellular brain iPS cell platform to identify drug targets, to optimize leads, and to conduct preclinical and clinical studies.
Who we are
MCM6 is an early-stage biotechnology company developing differentiated small-molecule and antisense oligonucleotide (ASO) therapeutics.
We are scientist-entrepreneurs dedicated to discovering new therapeutic agents for Alzheimer’s patients.
Supported by an STTR Phase 1 and Phase 2 grant from the National Institute on Aging (NIA/NIH), we are advancing disease-modifying candidates to address a profound unmet need.
What we do
Science
The APOE4 isoform impairs glial lipid efflux and neuron–glia trafficking of cholesterol and other lipids, leading to aberrant lipid accumulation that initiates disease pathology.
Currently approved therapeutics target amyloid, tau, and synaptic transmission but not lipid homeostasis.
MCM6’s specific aim is to focus on this therapeutic gap by targeting lipid metabolism and restoring lipid homeostasis using stem cell–based technology and validated platforms.
Team
The team combines drug-discovery experience with expertise in APOE4 biology. Our goal is to target mechanisms of APOE4 cerebrovascular dysfunction and amyloid accumulation in Alzheimer’s disease.
The founders have experience in advanced programs spanning from target identification through lead optimization toward preclinical candidates.
The underlying science originates from the Blanchard Lab at Mount Sinai, and MCM6 is actively collaborating to advance into future IND-enabling studies.
Our story
In 1906, Dr. Alois Alzheimer described the neuropathological hallmarks of the disease that now bears his name. In Roman numerals, 1906 is MCMVI — the origin of the name MCM6.
Founded in recognition of that milestone, MCM6 is developing therapeutics to restore lipid homeostasis in APOE4 carriers, the largest genetic risk group for Alzheimer’s disease.
Pipeline
MCM6 translates biological knowledge of APOE4 lipid biology into druggable targets. Validation and lead optimization are underway. Next steps include identifying preclinical candidates and conducting IND-enabling studies.
Platform Capabilities
Established HCS (High-content screening) using human APOE4 iPSC-derived 2D neuronal cells and validated the leads with 3-D miBRAIN 3D multi-cell-based platform, ready for preclinical studies.
Current Progress
Target validation and lead optimization are underway, supported by NIA/NIH STTR Phase 1 and Phase 2 grant funding.
Next Milestones
Selection of preclinical candidates, IND-enabling studies and strategic partnerships to accelerate clinical development. MCM6 is advancing a portfolio of candidates with the potential to become first-in-class disease-modifying therapies for APOE4-associated Alzheimer’s disease.
Investment opportunity
MCM6 offers investors a compelling entry point into precision neuroscience, with a focus on APOE4 therapeutics.
The MCM6 team and our platform are designed to support our current and future drug discovery programs. Funding is secured to validate drug targets and support lead optimization for the current proof-of-concept programs. We are progressing toward milestones, including preclinical candidate selection and IND-enabling studies. Leveraging our lipid biology expertise and the human 3D cell-based miBRAIN platform, we are positioned as a drug discovery engine to identify novel drug targets and chart a unique, successful path to IND studies.
Qualified investors are invited to contact MCM6.